Wellbutrin (bupropion HCl) tablets
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – May 2010
- Addition of pharmacokinetic information from a series of studies concerning drug interactions between bupropion and ritonavir and lopinavir/ritonavir.
- Addition of ticlopidine and clopidogrel as examples of drugs that are substrates of or inhibitors/inducers of CYP2B6 and thus may interact with bupropion. Addition of statement that bupropion increases the Cmax and AUC of citalopram by 30% and 40%, respectively.
(Wellbutrin XL and SR only)
- An update to the statement “Do not chew, divide, or crush tablets” to add “as this may lead to an increased risk of adverse effects, including seizures”.